Ashok Yadav/LinkedIn
Feb 26, 2026, 15:39
Ashok Yadav: Placental Glycogen as a Vital Energy Reserve for Fetal and Placental Health
Ashok Yadav, Biology Educator of Biology Faculty at Apex Academy, shared a post on LinkedIn:
”Placental glycogen storage serves as a vital energy reserve, primarily thought to support fetal growth and maintain glucose levels when maternal supply fluctuates. While its exact function in humans is still debated, animal models provide significant evidence for its role in both fetal development and placental health.
Functions of Placental Glycogen
- Fetal Energy Support: It is widely hypothesized that placental glycogen acts as a ‘buffer,’releasing glucose during periods of high fetal demand, particularly in late gestation.
- Local Placental Fuel: The placenta is a highly metabolic organ; glycogen stores may provide direct energy for its own functions, such as hormone production and maintaining vasomotor activity in placental blood vessels.
- Pathological Protection: In cases of maternal diabetes, the placenta may store excess glucose as glycogen to protect the fetus from hyperglycemia.
Dynamics and Storage Locations
- Temporal Peaks: In humans, glycogen accumulation peaks in the first trimester and declines toward term. In mice, it peaks around embryonic day 15.5.
- Cellular Storage:
- Mice: Specialized glycogen trophoblast cells in the junctional zone are the primary storage site.
- Humans: Storage occurs in extravillous trophoblasts (EVTs) located in the basal plate.
Clinical Significance
- Growth Complications: Both abnormally high and low placental glycogen levels are linked to Intrauterine Growth Restriction (IUGR) and pre-eclampsia.
- Diabetes: Maternal diabetes often leads to aberrant glycogen storage, which can disrupt normal metabolic communication between mother and fetus.
- Genetic Disorders: Rare conditions like Glycogen Storage Disease Type IV can show specific placental involvement, potentially allowing for prenatal diagnosis via biopsy.”
Stay updated with Hemostasis Today.
-
Sep 3, 2026, 10:56Elias Othman: Can an Enzyme Involved in Cell Signaling Become a Target for Antithrombotic Drug Discovery?
-
Sep 3, 2026, 10:42Jared Griffard: Hemorrhagic Shock and Component Blood Transfusion
-
Sep 3, 2026, 10:31Alan Nurden: Comparing Antiplatelet and Antithrombin Therapies in Coronary Microcirculation
-
Sep 3, 2026, 08:53Jamie’s Journey Through a Decade with Immune Thrombocytopenia – ITP Support Association
-
Sep 3, 2026, 08:00Beth Meneley: When Transfusion Is Not an Option – HBOT for Exceptional Blood Loss Anemia
-
Sep 3, 2026, 06:27Seyed Mehrab Safdari: Unmasking Factor VII Padua to Prevent Unnecessary Therapy and Thrombotic Risk
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?
-
Sep 3, 2026, 04:01Marianne Yee: Supporting Families and Transformative Therapies in Sickle Cell Disease
-
Sep 3, 2026, 03:51Strengthening Bleeding Disorders Care in New Zealand – WFH